methamphetamine has been researched along with naltrexone in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.63) | 18.7374 |
| 1990's | 4 (10.53) | 18.2507 |
| 2000's | 5 (13.16) | 29.6817 |
| 2010's | 17 (44.74) | 24.3611 |
| 2020's | 11 (28.95) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hamada, T; Kameyama, T; Nakayama, S; Ukai, M | 1 |
| Misawa, M; Mori, T; Nagase, H; Suzuki, T; Tsuji, M | 2 |
| Kameyama, T; Toyoshi, T; Ukai, M | 1 |
| Andrews, AM; Cadet, JL; Chiueh, CC; Ladenheim, B; Su, TP; Tsao, LI | 1 |
| Anggadiredja, K; Hiranita, T; Sakimura, K; Yamamoto, T | 1 |
| Chiu, CT; Ho, IK; Ma, T | 1 |
| Kast, RE | 1 |
| McGregor, IS; van Nieuwenhuijzen, PS | 1 |
| Grant, JE; Kim, SW; Odlaug, BL | 1 |
| Baumann, MH; Bossert, JM; Hutchinson, MR; Kambhampati, S; Li, X; Pickens, CL; Rice, KC; Shaham, Y; St Laurent, R; Theberge, FR; Watkins, LR | 1 |
| Fukushima, Y; Hall, FS; Kitanaka, J; Kitanaka, N; Kubo, H; Morita, Y; Nishiyama, N; Sawai, T; Takahashi, H; Takemura, M; Tanaka, K; Tatsuta, T; Uhl, GR; Watabe, K | 1 |
| Eastwood, EC; Phillips, TJ | 1 |
| Glaser, PE; Hays, LR; Pike, E; Rush, CR; Stoops, WW | 1 |
| Crawford, E; Edwards, S; George, O; Gould, A; Grant, Y; Koob, GF; Schlosburg, JE; Vendruscolo, LF; Wee, S; Whitfield, TW; Zamora-Martinez, ER | 1 |
| Bujarski, S; Courtney, KE; Heinzerling, K; Leventhal, AM; London, ED; Lunny, K; Miotto, K; Moallem, NR; Ray, LA; Roche, D; Shoptaw, S | 1 |
| Batki, SL; Coffin, P; DeMartini, A; Euren, J; Hahn, JA; Huffaker, S; Matheson, T; Rowe, C; Santos, D; Santos, GM; Vittinghoff, E; Vlahov, D | 1 |
| Glaser, PE; Hays, LR; Lile, JA; Marks, KR; Rush, CR; Stoops, WW | 1 |
| Courtney, KE; Ghahremani, DG; Ray, LA | 1 |
| Bujarski, S; Courtney, KE; London, ED; Ray, LA; Roche, DJO; Shoptaw, S; Worley, MJ | 1 |
| Batki, SL; Coffin, PO; Colfax, G; Hern, J; Matheson, T; Santos, D; Santos, GM; Vittinghoff, E | 1 |
| Dennis, LE; Hoffman, WF; Kohno, M; Korthuis, PT; McCready, H; Schwartz, DL | 1 |
| Anand, S; Chan, EW; Lam, L; Li, X; Tse, ML; Zhao, JX | 1 |
| Dong, GM; Guo, LK; Li, J; Lu, GY; Ma, CM; Song, R; Wang, ZY; Wu, N; Zhang, RL | 1 |
| Courtney, KE; Green, R; Grodin, EN; Lim, AC; London, ED; Meredith, LR; Moallem, NR; Ray, LA; Sayegh, P; Venegas, A | 1 |
| Dong, GM; Guo, LK; Han, X; Li, J; Ma, CM; Song, R; Wang, ZY; Wu, N | 1 |
| Bart, G; Carmody, T; Coffin, P; Dela Cruz, A; Ghitza, UE; Kim, M; Ling, W; Nunes, EV; Rush, AJ; Schmitz, J; Sharma, G; Shoptaw, S; Shores-Wilson, K; Sonne, SC; Sparenborg, S; Trivedi, MH; Wahle, A; Wakhlu, S; Walker, R; Wiest, K | 1 |
| Gainer, DM; Miller, SC; Nahhas, RW; Silverstein, SM; Vanderhoof, SO; Vanderhoof, T; Wright, MD | 1 |
| Castillo, F; Comer, SD; Jones, JD; Kranzler, HR; Manubay, J; Martinez, S; Mogali, S; Mumtaz, M; Perez, F; Pramanik, S; Vadhan, NP | 1 |
| Campbell, ANC; Choo, TH; Cook, RR; Lee, JD; Nunes, EV; Pavlicova, M; Rotrosen, J; Shulman, M; Tsui, JI | 1 |
| Carmody, T; Northrup, TF; Schmitz, JM; Shoptaw, S; Stotts, AL; Trivedi, MH; Villarreal, YR; Weaver, MF; Yammine, L; Yoon, JH | 1 |
| Carmody, T; Cook, RR; Korthuis, PT; Levander, XA; Potter, JS; Shoptaw, S; Trivedi, MH | 1 |
| Carmody, TJ; Coffin, PO; Kidd, JD; Levin, FR; Nunes, EV; Shoptaw, SJ; Smiley, SL; Trivedi, MH | 1 |
| Nawata, Y; Nishioku, T; Ooishi, R; Yamaguchi, T | 1 |
| Chan, MH; Chen, HH; Chen, LC | 1 |
3 review(s) available for methamphetamine and naltrexone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Use of FDA approved methamphetamine to allow adjunctive use of methylnaltrexone to mediate core anti-growth factor signaling effects in glioblastoma.
Topics: Brain Neoplasms; Central Nervous System Stimulants; Drug Approval; Drug Synergism; Glioblastoma; Humans; Methamphetamine; Naltrexone; Narcotic Antagonists; Neovascularization, Pathologic; Quaternary Ammonium Compounds; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2009 |
Efficacy and safety of naltrexone for amfetamine and methamfetamine use disorder: a systematic review of randomized controlled trials.
Topics: Amphetamine; Amphetamine-Related Disorders; Humans; Methamphetamine; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
12 trial(s) available for methamphetamine and naltrexone
| Article | Year |
|---|---|
A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence.
Topics: Acetylcysteine; Adult; Amphetamine-Related Disorders; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methamphetamine; Middle Aged; Naltrexone; Young Adult | 2010 |
The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study.
Topics: Adult; Amphetamine-Related Disorders; Analysis of Variance; Blood Pressure; Cross-Over Studies; Cues; Double-Blind Method; Female; Heart Rate; Humans; Male; Methamphetamine; Middle Aged; Naltrexone; Narcotic Antagonists; Sex Characteristics; Surveys and Questionnaires; Time Factors; Young Adult | 2015 |
Feasibility, Acceptability, and Tolerability of Targeted Naltrexone for Nondependent Methamphetamine-Using and Binge-Drinking Men Who Have Sex with Men.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Binge Drinking; Condoms; Counseling; Double-Blind Method; Homosexuality, Male; Humans; Male; Methamphetamine; Middle Aged; Naltrexone; Narcotic Antagonists; Placebos; Risk Reduction Behavior; Risk-Taking; Sexual Behavior; Substance-Related Disorders; Unsafe Sex; Young Adult | 2016 |
The Effects of Pharmacological Opioid Blockade on Neural Measures of Drug Cue-Reactivity in Humans.
Topics: Adult; Behavior, Addictive; Brain; Brain Mapping; Central Nervous System Stimulants; Cues; Female; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Methamphetamine; Naltrexone; Narcotic Antagonists; Oxygen; Substance-Related Disorders | 2016 |
Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial.
Topics: Adult; Amphetamine-Related Disorders; Delayed-Action Preparations; Double-Blind Method; Homosexuality, Male; Humans; Male; Methamphetamine; Naltrexone; Narcotic Antagonists; San Francisco; Treatment Outcome | 2018 |
A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder.
Topics: Adult; Amphetamine-Related Disorders; Amygdala; Delayed-Action Preparations; Female; Hippocampus; Humans; Magnetic Resonance Imaging; Male; Methamphetamine; Middle Aged; Naltrexone; Narcotic Antagonists; Neural Pathways; Rest; Ventral Striatum | 2018 |
Bupropion and Naltrexone in Methamphetamine Use Disorder.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amphetamine-Related Disorders; Bupropion; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Injections; Male; Medication Adherence; Methamphetamine; Middle Aged; Naltrexone; Narcotic Antagonists; Young Adult | 2021 |
The effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward/punishment sensitivity and methamphetamine's effects.
Topics: Adult; Central Nervous System Stimulants; Double-Blind Method; Female; Humans; Male; Methamphetamine; Naltrexone; Punishment; Reward | 2022 |
Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone.
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Humans; Injections, Intramuscular; Methamphetamine; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2022 |
Naltrexone plus bupropion reduces cigarette smoking in individuals with methamphetamine use disorder: A secondary analysis from the CTN ADAPT-2 trial.
Topics: Bupropion; Cigarette Smoking; Humans; Methamphetamine; Naltrexone; Narcotic Antagonists; Prospective Studies | 2023 |
A gender-based secondary analysis of the ADAPT-2 combination naltrexone and bupropion treatment for methamphetamine use disorder trial.
Topics: Adult; Bupropion; Central Nervous System Stimulants; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methamphetamine; Naltrexone; Pregnancy | 2023 |
Sexual orientation differences among men in a randomized clinical trial of extended-release naltrexone and bupropion for methamphetamine use disorder.
Topics: Bupropion; Double-Blind Method; Female; Homosexuality, Male; Humans; Male; Methamphetamine; Naltrexone; Prospective Studies; Sexual and Gender Minorities; Sexual Behavior | 2023 |
23 other study(ies) available for methamphetamine and naltrexone
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Discriminative stimulus properties of the mixed agonist-antagonist pentazocine in the rat using two-choice discrete-trial avoidance paradigm.
Topics: Animals; Discrimination, Psychological; Dose-Response Relationship, Drug; Male; Methamphetamine; Naltrexone; Narcotics; Pentazocine; Pentobarbital; Rats; Rats, Inbred Strains | 1989 |
The role of delta-opioid receptor subtypes in cocaine- and methamphetamine-induced place preferences.
Topics: Animals; Benzylidene Compounds; Cocaine; Conditioning, Psychological; Male; Methamphetamine; Naltrexone; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Reinforcement, Psychology | 1994 |
DAMGO ([D-Ala2,NMePhe4,Gly-ol]enkephalin), but not DPLPE ([D-Pen2,L- Pen5]enkephalin), specifically inhibits methamphetamine-induced behavioral responses in the mouse.
Topics: Analgesics; Animals; Behavior, Animal; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, D-Penicillamine (2,5)-; Enkephalins; Injections, Intraventricular; Male; Methamphetamine; Mice; Mice, Inbred Strains; Naltrexone; Narcotic Antagonists | 1993 |
The role of delta-opioid receptors in the discriminative stimulus properties of a low dose of methamphetamine.
Topics: Animals; Benzylidene Compounds; Central Nervous System Stimulants; Discrimination, Psychological; Dose-Response Relationship, Drug; Male; Methamphetamine; Naltrexone; Quinolines; Rats; Rats, Inbred F344; Receptors, Opioid, delta | 1997 |
Delta opioid peptide [D-Ala2,D-leu5]enkephalin blocks the long-term loss of dopamine transporters induced by multiple administrations of methamphetamine: involvement of opioid receptors and reactive oxygen species.
Topics: Animals; Antioxidants; Body Temperature; Carrier Proteins; Dopamine Plasma Membrane Transport Proteins; Enkephalin, Leucine-2-Alanine; Glutathione; Male; Membrane Glycoproteins; Membrane Transport Proteins; Methamphetamine; Mice; Naltrexone; Nerve Tissue Proteins; Reactive Oxygen Species; Receptors, Opioid | 1998 |
Naltrexone attenuates cue- but not drug-induced methamphetamine seeking: a possible mechanism for the dissociation of primary and secondary reward.
Topics: Animals; Behavior, Addictive; Central Nervous System Stimulants; Conditioning, Operant; Male; Methamphetamine; Naltrexone; Narcotic Antagonists; Rats; Reward; Self Administration | 2004 |
Attenuation of methamphetamine-induced behavioral sensitization in mice by systemic administration of naltrexone.
Topics: Amphetamine-Related Disorders; Animals; Behavior, Animal; Brain; Central Nervous System Stimulants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Male; Methamphetamine; Mice; Naltrexone; Narcotic Antagonists | 2005 |
Sedative and hypothermic effects of gamma-hydroxybutyrate (GHB) in rats alone and in combination with other drugs: assessment using biotelemetry.
Topics: Animals; Baclofen; Benzazepines; Dose-Response Relationship, Drug; Drug Interactions; Drug Tolerance; Flumazenil; Hypothermia; Illicit Drugs; Male; Methamphetamine; Morpholines; Motor Activity; N-Methyl-3,4-methylenedioxyamphetamine; Naltrexone; Rats; Rats, Wistar; Ritanserin; Sodium Oxybate; Telemetry | 2009 |
Effect of chronic delivery of the Toll-like receptor 4 antagonist (+)-naltrexone on incubation of heroin craving.
Topics: Animals; Behavior, Addictive; Conditioning, Operant; Cues; Dose-Response Relationship, Drug; Drug Administration Schedule; Extinction, Psychological; Heroin; Infusion Pumps, Implantable; Methamphetamine; Naltrexone; Narcotic Antagonists; Rats; Self Administration; Stereoisomerism; Time Factors; Toll-Like Receptor 4 | 2013 |
The selective μ opioid receptor antagonist β-funaltrexamine attenuates methamphetamine-induced stereotypical biting in mice.
Topics: Animals; Behavior, Animal; Central Nervous System Stimulants; Male; Methamphetamine; Mice; Mice, Inbred ICR; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu; Stereotyped Behavior | 2013 |
Morphine intake and the effects of naltrexone and buprenorphine on the acquisition of methamphetamine intake.
Topics: Amphetamine-Related Disorders; Animals; Buprenorphine; Choice Behavior; Female; Inbreeding; Male; Methamphetamine; Mice; Morphine; Naltrexone; Narcotic Antagonists; Selection, Genetic | 2014 |
Naltrexone and bupropion, alone or combined, do not alter the reinforcing effects of intranasal methamphetamine.
Topics: Administration, Intranasal; Adult; Bupropion; Humans; Methamphetamine; Naltrexone; Narcotic Antagonists; Surveys and Questionnaires | 2015 |
κ Opioid receptors in the nucleus accumbens shell mediate escalation of methamphetamine intake.
Topics: Analysis of Variance; Animals; Central Nervous System Stimulants; Conditioning, Operant; Enkephalins; Male; Methamphetamine; Naltrexone; Narcotic Antagonists; Nucleus Accumbens; Protein Precursors; Rats; Rats, Wistar; Receptors, Opioid, kappa; Reinforcement, Psychology; Self Administration | 2015 |
Separate and Combined Effects of Naltrexone and Extended-Release Alprazolam on the Reinforcing, Subject-Rated, and Cardiovascular Effects of Methamphetamine.
Topics: Administration, Intranasal; Adult; Alprazolam; Amphetamine-Related Disorders; Blood Pressure; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; GABA Modulators; Heart Rate; Humans; Male; Methamphetamine; Middle Aged; Naltrexone; Narcotic Antagonists; Psychomotor Performance; Reinforcement, Psychology; Self Administration | 2016 |
Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with methamphetamine use disorder.
Topics: Anxiety; Behavior, Addictive; Conditioning, Psychological; Craving; Cues; Data Collection; Double-Blind Method; Emotions; Humans; Methamphetamine; Naltrexone; Time Factors | 2017 |
Inhibition of naltrexone on relapse in methamphetamine self-administration and conditioned place preference in rats.
Topics: Animals; Conditioning, Operant; Cues; Dose-Response Relationship, Drug; Drug-Seeking Behavior; Male; Methamphetamine; Naltrexone; Rats; Rats, Sprague-Dawley; Reinforcement, Psychology; Self Administration; Spatial Behavior | 2019 |
Executive function moderates naltrexone effects on methamphetamine-induced craving and subjective responses.
Topics: Adult; Amphetamine-Related Disorders; Central Nervous System Stimulants; Cognition; Craving; Cross-Over Studies; Double-Blind Method; Executive Function; Female; Humans; Los Angeles; Male; Methamphetamine; Naltrexone; Narcotic Antagonists; Young Adult | 2020 |
Naltrexone attenuates methamphetamine-induced behavioral sensitization and conditioned place preference in mice.
Topics: Amphetamine-Related Disorders; Animals; Behavior, Animal; Central Nervous System Sensitization; Central Nervous System Stimulants; Conditioning, Classical; Disease Models, Animal; Extinction, Psychological; Male; Mental Recall; Methamphetamine; Mice; Motivation; Naltrexone; Narcotic Antagonists | 2021 |
Exploring the Interactions between Non-Medical Methamphetamine Use and Prescribed Buprenorphine or Naltrexone in Opioid Use Disorder Treatment Retention.
Topics: Buprenorphine; Delayed-Action Preparations; Humans; Injections, Intramuscular; Methamphetamine; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retrospective Studies | 2021 |
Nalmefene attenuates reinstatement of methamphetamine-seeking behavior in rats through group II metabotropic glutamate receptors (mGluR2/3).
Topics: Animals; Cues; Drug-Seeking Behavior; Extinction, Psychological; Methamphetamine; Naltrexone; Rats; Receptors, Metabotropic Glutamate; Self Administration | 2024 |
Extinction and reinstatement of methamphetamine-induced conditioned place preference in zebrafish.
Topics: Animals; Clonidine; Extinction, Psychological; Methamphetamine; Morphine; Naltrexone; Recurrence; Zebrafish | 2023 |